Peginterferon and other interferons for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Peginterferon and other interferons for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Peginterferon and other interferons for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library antiviral, antiviral...
BioPortfolio Limited Both GSK and Gilead are obvious candidates and in light of similar challenges between HBV/HCV and HIV, Datamonitor expects increased portfolio synergies for the management of chronic viral conditions; 10 Summary 11 Key metrics 12 CHAPTER 2 MARKET SEGMENTATION & DEFINITION 29 Strategic scope and focus 29 Market definition 30 Hepatitis B 30 Disease definition 30 Epidemiology 34...
http://www.amarbio.com/AJVR.pdf page 10
Database P P - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Therapeutic Biological Approvals 1 DNA Way MS#48 South San Francisco, CA 95080 Lincense 1048 - 2/26/2004 AVONEX Interferon beta-1a Treatment of multiple sclerosis (orphan indication) - Biogen, IncInfergen Interferon alfacon -1 Treatment of chronic hepatitis C virus (HCV) infection in patients 18 years of age or older with compensated liver disease who...
Office of Drug Safety: Patient Labeling and Risk Communitation Food and Drug Administration • Center for Drug Evaluation and Research Office of Drug Safety Search Patient Labeling and Risk Communication FDA-Approved Patient Labeling Patient Package Inserts.- For some prescription medicines, FDA approves special patient materials to instruct patients about the safe use of the product
author: PhillipsJ
Approved Biotechnology Drugs, 2002 - Imaging agent for use in echocardiography - Jun 2002 Infergen ® (interferon alfacon -1) - InterMune Pharmaceuticals, Inc., and Amgen - Treatment of hepatitis C (HCV) in patients 18 years or older with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA; subsequent treatment of HCV-infected patients who have tolerated...
CWW0745_Nov10.qxd page 6
author: Leslie
duplicates:http://www.phaseforward.com/news/media/2003_11_10.pdf
Interferon alfacon-1 - Product Approval Information - Licensing Action In accordance with approved labeling, your product will bear the tradename Infergen, and will be marketed in single-use vials containing either 9 ug or 15 ug Interferon alfacon -1 1, 1997 in which you commit to conduct a randomized, multicenter, controlled study to assess the safety and efficacy of Interferon ...
Interferon alfacon-1 - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Interferon alfacon -1 Product Approval Information - Licensing Action Proper name: Interferon alfacon -1 Tradename: Infergen Manufacturer: InterMune, Inc, Brisbane, CA, License #1626 Revised: To provide a Medication Guide Approval Date: 11/4/2002 Type...
Interferon alfacon-1 - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Interferon alfacon -1 Product Approval Information - Licensing Action Proper name: Interferon alfacon -1 Tradename: Infergen Manufacturer: Amgen, Inc, Thousand Oaks, CA, License #1080 Indication for Use: Treatment of chronic hepatitis C virus (HCV)...
http://www.easy.no/affitech/pdf/das1.pdf page 1
duplicates:http://www.iscpubs.com/articles/abl/b0002das.pdf
Prescription Drug User Fee Act - User Fee Billable Therapeutic Products: Approved Under Section 351 of the PHS Act IU/mL Corixa Corp License 1614 Bexxar Tositumomab and Iodine I-131 Tositumomab 125011/0 6/27/2003 Therapeutic Regimen Cytogen Corp License 1164 ProstaScint Capromab Pendetide 103608/0 10/28/1996 0.5 mg/mL Elan Pharmaceuticals License 1579 MYOBLOC Botulinum Toxin Type B 103846/0 12/8/2000 5,000 IU/mL Eli Lilly & Company License 1611 Xigris Drotrecogin alfa (Activated) 125029/0 11/21...
Interferon alfacon-1, Infergen, Amgen page 12
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 11
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 10
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 9
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 8
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 7
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 6
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 5
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 4
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 3
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 2
author: CBER FDA
Interferon alfacon-1, Infergen, Amgen page 1
author: CBER FDA
